Breaking news! Anke Bio welcomes a new CEO

（Source: Yidu Medicine）

On April 2, 2026, Anhui Anke Bioengineering (Group) Co., Ltd. announced a major personnel appointment. Dr. Dou Changlin, an internationally renowned biopharmaceutical innovation expert and former Chief Operating Officer and R&D President of Boan Biotech, officially joined the company to serve as CEO and Chief Scientist, fully steering core work including the construction of the R&D system, the building of cutting-edge technology platforms, and global expansion and layout, helping the company move toward becoming a globally leading innovative drug enterprise.

Public information shows that Dr. Dou Changlin, born in 1963, holds U.S. citizenship. He is a seasoned expert in the global biopharmaceutical field, and is also a core founder of Boan Biotech. He received a Bachelor’s degree in Biology from Peking University in July 1984, a Master’s degree from the Institute of Neuroscience, Chinese Academy of Sciences in March 1988, and a Ph.D. degree from the State University of New York at Stony Brook in 1995, and completed postdoctoral research at the Sloan-Kettering Cancer Center in the United States.

From 1995 to 2013, Dr. Dou successively worked at several leading global biopharmaceutical institutions in the United States, including Regeneron, Genentech, and Invitrogen. He held positions such as Senior Scientist and Team Leader, and led antibody drug research and development as well as high-expression technology and process development work. During this period, as an inventor, he obtained multiple U.S. patents, and his R&D results were applied in multiple globally marketed drugs.

In 2012, he returned to China in the capacity of Shandong Province’s “Taishan Scholar Overseas Distinguished Expert.” In December 2013, he joined Boan Biotech, responsible for the company’s early-stage establishment and the building of technology platforms. He later served as R&D President, Chief Operating Officer, Executive Director, and Chairman of the Strategy Committee, fully leading the company’s R&D strategy, product line development, and the CMC system construction. He successfully helped three antibody drugs, including Boyunuo, go on the market in China, and led nine products into clinical stages in China, the U.S., Europe, and Japan.

On March 31, 2026, due to reaching the statutory retirement age, Dr. Dou resigned from all positions at Boan Biotech.

Regarding compensation, according to Boan Biotech’s publicly disclosed information, his annual remuneration during his tenure was 7.224 million RMB.

In April 2026, he joined Anke Bio and served as CEO and Chief Scientist.

A wealth of information and precise interpretation—available in the Sina Finance APP